Dr Stephen Griffin, associate professor in the School of Medicine at the University of Leeds, said: “The success of these antivirals potentially marks a new era in our ability to prevent the severe consequences of SARS-CoV2 [coronavirus] infection, and is also a vital element for the care of clinically vulnerable people who may be unable to either receive or respond to vaccines.”
